You just read:

Aprea Therapeutics Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with APR-246 in Presentation at 2016 European Society for Medical Oncology (ESMO) Annual Meeting

News provided by

Aprea Therapeutics AB

Oct 10, 2016, 03:00 ET